{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium-glucose+cotransporter-2+inhibitors+%28SGLT2i%29", "query": { "intervention": "Sodium-glucose cotransporter-2 inhibitors (SGLT2i)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium-glucose+cotransporter-2+inhibitors+%28SGLT2i%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T19:58:40.232Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05990296", "title": "Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure", "Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "Multiprong CDS with referral to pharmacist co-management", "type": "BEHAVIORAL" }, { "name": "Multiprong CDS with GDMT order set", "type": "BEHAVIORAL" }, { "name": "Focused education", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4306, "start_date": "2023-08-01", "completion_date": "2025-05-17", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Danville, Pennsylvania", "locations": [ { "city": "Danville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05990296" }, { "nct_id": "NCT05073692", "title": "Comparison of Type 2 Diabetes Pharmacotherapy Regimens", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 2 Diabetes Mellitus", "Cardiovascular Diseases" ], "interventions": [ { "name": "SU", "type": "DRUG" }, { "name": "DPP4", "type": "DRUG" }, { "name": "SGLT2i", "type": "DRUG" }, { "name": "GLP-1RA", "type": "DRUG" }, { "name": "SGLT2i or GLP-1RA", "type": "DRUG" }, { "name": "Linagliptin (DPP4)", "type": "DRUG" }, { "name": "Exenatide (GLP-1RA)", "type": "DRUG" }, { "name": "Liraglutide (GLP-1RA)", "type": "DRUG" }, { "name": "Empagliflozin (SGLT2i)", "type": "DRUG" }, { "name": "Glimepiride (SU)", "type": "DRUG" }, { "name": "Glipizide (SU)", "type": "DRUG" }, { "name": "Glimepiride (SU) or Glipizide (SU)", "type": "DRUG" }, { "name": "SU or DPP4 (excluding saxagliptin and alogliptin)", "type": "DRUG" }, { "name": "Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 241981, "start_date": "2021-07-01", "completion_date": "2025-03-12", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 6, "location_summary": "Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Pleasanton", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Bloomington", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05073692" }, { "nct_id": "NCT05834738", "title": "Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy", "Immunoglobulin A Nephropathy" ], "interventions": [ { "name": "Atrasentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2023-07-20", "completion_date": "2025-10-29", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Oak Brook", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05834738" }, { "nct_id": "NCT05640180", "title": "An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" }, { "name": "Sodium-glucose cotransporter-2 inhibitors (SGLT2i)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17847, "start_date": "2022-11-23", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2024-01-08", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05640180" }, { "nct_id": "NCT07172971", "title": "Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duchenne Muscular Dystrophy (DMD)" ], "interventions": [ { "name": "SGLT-2 inhibitor", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "18 Years", "sex": "MALE", "summary": "8 Years to 18 Years · Male only" }, "enrollment_count": 10, "start_date": "2026-07-01", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07172971" }, { "nct_id": "NCT06150924", "title": "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD", "type": "DRUG" }, { "name": "Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mineralys Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-12-14", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 44, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06150924" }, { "nct_id": "NCT06430684", "title": "Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Kidney Diseases", "Pediatric Kidney Disease" ], "interventions": [ { "name": "Empagliflozin 10 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "12 Years to 25 Years" }, "enrollment_count": 40, "start_date": "2024-08-23", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06430684" }, { "nct_id": "NCT06932081", "title": "Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Congenital Heart Disease", "Congenital Heart Disease", "Systemic Right Ventricle", "Transposition of the Great Arteries", "Congenitally Corrected Transposition of the Great Arteries", "Fontan", "Single Ventricle", "Tetralogy of Fallot (TOF)" ], "interventions": [ { "name": "SGLT2 inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leiden University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2023-01-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Grand Rapids, Michigan • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06932081" }, { "nct_id": "NCT06609356", "title": "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type 1 Diabetes Mellitus", "Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)", "MODY2 Diabetes", "Healthy Volunteer" ], "interventions": [ { "name": "Study Visit 1", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Study Visit 2", "type": "PROCEDURE" }, { "name": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2025-07-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06609356" }, { "nct_id": "NCT07444203", "title": "Transformative Research in Diabetic Nephropathy 2.0", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Nephropathies", "Kidney Diseases", "Renal Insufficiency, Chronic", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)", "type": "DRUG" }, { "name": "Renin-angiotensin-aldosterone system blockade", "type": "DRUG" }, { "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)", "type": "DRUG" }, { "name": "Mineralocorticoid Receptor Antagonists(MRAs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-11-12", "completion_date": "2028-11-12", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-09T19:58:40.232Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444203" } ] }